ERCC1和Survivin对非小细胞肺癌患者化疗效果的预测价值

Predictive value of ERCC1 and survivin for chemotherapy in patients with non-small cell lung cancer

目的探讨剪切修复偶联因子1(ERCC1)和存活蛋白(Survivin)对非小细胞肺癌患者化疗效果的预测价值。方法选择2015年1月到2017年1月在中国医科大学附属第四医院进行治疗的60例非小细胞肺癌患者资料进行回顾性分析,全部患者均给予化疗。检测ERCC1和Survivin在非小细胞肺癌患者中的表达,比较ERCC1和Survivin不同表达情况的化疗效果及生存情况。结果 ERCC1阴性患者的治疗效果优于ERCC1阳性患者,Survivin阴性患者的治疗效果优于Survivin阳性患者,差异均有统计学意义(χ~2=7.096、4.812,P均<0.05)。在16个月的随访中,38例患者死亡,病死率为63.33%。ERCC1阴性患者的生存时间为(11.92±4.23)月,ERCC1阳性患者的生存时间为(9.04±3.87)月,差异有统计学意义(χ~2=6.634,P<0.05)。Survivin阴性患者的生存时间为(12.58±3.87)月,Survivin阳性患者的生存时间为(9.77±4.89)月,差异有统计学意义(χ~2=4.931,P<0.05)。患者的年龄偏大、吸烟、分化程度较低、临床分期较高、ERCC1的表达为阳性、Survivin的表达为阳性,是经过化疗的非小细胞肺癌患者预后的影响因素(RR=2.349、10.216、6.378、26.258、7.729、8.837,P均<0.05)。结论 ERCC1和Survivin的表达与非小细胞肺癌患者的化疗效果和预后密切相关,可纳入对该种类疾病患者的疗效与预后推断的预测因子中。

Objective To investigate the predictive value of ERCC1 and survivin in the chemotherapy effect of patients with non-small cell lung cancer.Methods A retrospective analysis of 60 patients with non-small cell lung patients who were treated at the Fourth Affiliated Hospital of China Medical University between January 2015 and January 2017 was performed.All patients were given chemotherapy.The predictive values of ERCC1 and survivin in the chemotherapy effect of patients with non-small cell lung cancer were analyzed.Results The treatment effect of ERCC1 negative patients was better than that of ERCC1 positive patients;the treatment effect of survivin negative patients were better than survivin positive patients(χ~2=7.096,4.812,P<0.05).At 16 months of follow-up,38 patients died and the case fatality rate was 63.33%.The survival time of ERCC1-negative patients was(11.92±4.23)months,and the survival time of ERCC1-positive patients was(9.04±3.87)months.The data were statistically significant(χ~2=6.634,P<0.05).Survivin-negative patients had a survival time of(12.58±3.87)months,and survivin-positive patients had a survival time of(9.77±4.89)months.The difference between the two groups was statistically significant(χ~2=4.931,P<0.05).Patients with older age,smoking,lower degree of differentiation of the cancer cells,higher clinical stage,ERCC1 positive and survivin positive were the prognostic factor of patients with non-small cell lung cancer after chemotherapy(RR=2.349,10.216,6.378,26.258,7.729,8.837,P<0.05).Conclusion The expressions of ERCC1 and survivin were closely related to the effect of chemotherapy and prognosis in non small cell lung cancer patients.It is worthy of in-depth study and may be included in the predictors of the efficacy and prognosis of the patients of this kind of disease.